Publicaciones en colaboración con investigadores/as de Instituto de Química Médica (32)

2024

  1. TRP14 is the rate-limiting enzyme for intracellular cystine reduction and regulates proteome cysteinylation

    EMBO Journal, Vol. 43, Núm. 13, pp. 2789-2812

  2. The CB1 receptor interacts with cereblon and drives cereblon deficiency-associated memory shortfalls

    EMBO Molecular Medicine, Vol. 16, Núm. 4, pp. 755-783

2023

  1. Thienopyrimidine Derivatives as GPR55 Receptor Antagonists: Insight into Structure-Activity Relationship

    ACS Medicinal Chemistry Letters, Vol. 14, Núm. 1, pp. 18-25

2022

  1. Editorial: Cannabinoids as potential treatment for neurological diseases

    Frontiers in Neuroscience

2021

  1. Delayed alveolar clearance of nanoparticles through control of coating composition and interaction with lung surfactant protein A

    Materials Science and Engineering C

  2. Preclinical investigation in neuroprotective effects of the gpr55 Ligand VCE-006.1 in experimental models of Parkinson’s disease and amyotrophic lateral sclerosis

    Molecules, Vol. 26, Núm. 24

  3. Targeting nuclear protein TDP-43 by cell division cycle kinase 7 inhibitors: A new therapeutic approach for amyotrophic lateral sclerosis

    European Journal of Medicinal Chemistry, Vol. 210

2019

  1. 11PS04 is a new chemical entity identified by microRNA-based biosensing with promising therapeutic potential against cancer stem cells

    Scientific Reports, Vol. 9, Núm. 1

  2. Structure-Guided Tuning of a Selectivity Switch towards Ribonucleosides in Trypanosoma brucei Purine Nucleoside 2′-Deoxyribosyltransferase

    ChemBioChem, Vol. 20, Núm. 24, pp. 2996-3000

2017

  1. 2′-Deoxyribosyltransferase from Leishmania mexicana, an efficient biocatalyst for one-pot, one-step synthesis of nucleosides from poorly soluble purine bases

    Applied Microbiology and Biotechnology, Vol. 101, Núm. 19, pp. 7187-7200

  2. Corrigendum to “Biological characterization of PM226, a chromenoisoxazole, as a selective CB2 receptor agonist with neuroprotective profile” [Pharmacol. Res. (2016) 110(2016) (205–215)] (S1043661816302080) (10.1016/j.phrs.2016.03.021)

    Pharmacological Research

  3. New pyridazinone-4-carboxamides as new cannabinoid receptor type-2 inverse agonists: Synthesis, pharmacological data and molecular docking

    European Journal of Medicinal Chemistry, Vol. 127, pp. 398-412

2016

  1. Biological characterization of PM226, a chromenoisoxazole, as a selective CB2 receptor agonist with neuroprotective profile

    Pharmacological Research, Vol. 110, pp. 205-215

  2. Chromenopyrazole, a Versatile Cannabinoid Scaffold with in Vivo Activity in a Model of Multiple Sclerosis

    Journal of Medicinal Chemistry, Vol. 59, Núm. 14, pp. 6753-6771

  3. Exploring the Benzimidazole Ring as a Substitution for Indole in Cannabinoid Allosteric Modulators

    Cannabis and Cannabinoid Research, Vol. 1, Núm. 1, pp. 196-201

  4. Identification of Novel GPR55 Modulators Using Cell-Impedance-Based Label-Free Technology

    Journal of Medicinal Chemistry, Vol. 59, Núm. 5, pp. 1840-1853

  5. Targeting cannabinoid CB2 receptors in the central nervous system. Medicinal chemistry approaches with focus on neurodegenerative disorders

    Frontiers in Neuroscience, Vol. 10, Núm. SEP

2015

  1. Selective, nontoxic CB2 cannabinoid o-quinone with in vivo activity against triple-negative breast cancer

    Journal of Medicinal Chemistry, Vol. 58, Núm. 5, pp. 2256-2264

  2. Synthesis, pharmacological evaluation and docking studies of pyrrole structure-based CB2 receptor antagonists

    European Journal of Medicinal Chemistry, Vol. 101, pp. 651-667

  3. The melatonin- N,N-dibenzyl(N-methyl)amine hybrid ITH91/IQM157 affords neuroprotection in an in vitro Alzheimer's model via hemo-oxygenase-1 induction

    ACS Chemical Neuroscience, Vol. 6, Núm. 2, pp. 288-296